The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Yaqrit appoints Troels Jordansen as new CEO to drive late clinical development and commercial strategy
Jan 10, 2025•over 1 year ago
Contract Type
partnership
LondonBiotechnologyHealth CareTherapeutics
Description
Yaqrit announced the appointment of Troels Jordansen as its new CEO to lead the development of late-stage trials for the treatment of complications associated with advanced liver disease and to prepare for the launch of a phase 3 study. Jordansen's extensive experience in strategic planning and executing partnerships with companies developing complex advanced therapies is expected to contribute to assembling a powerful and experienced management team to realize the value of Yaqrit's pipeline of drugs and devices addressing unmet needs.
Company Information
Company
Yaqrit
Location
London, England, United Kingdom
About
Yaqrit is a clinical-stage company discovering and developing innovative treatments for patients with advanced liver disease at high risk of hospitalization and death. Yaqrit’s pipeline includes novel therapeutics in phase 2 / 3 clinical trials and two medical devices entering registrational trials providing acute and chronic treatments for advanced cirrhosis and acute-on-chronic liver failure, where there is an urgent need for more effective treatments.
LondonBiotechnologyHealth CareTherapeutics